Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKI
Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · May 29, 2018
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In the pediatric population, acute kidney injury (AKI) is commonly observed in critically ill patients. At this time, there are no standardized care pathways that begin at identifying patients at risk for developing AKI and progress through to early recognition and treatment. Through previous work, the investigators have developed, tested, and integrated an AKI risk-stratification/clinical recognition tool (RAI) and a urine biomarker (NGAL) to try to identify patients at risk vs. not at-risk for developing AKI. However, these factors alone have yet to be integrated into clinical decision su...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to the Pediatric Intensive Care Unit (PICU)
- • Renal Angina Index (RAI) greater than or equal to 8
- • Urine NGAL greater than or equal to 150 ng/mL
- • Indwelling urinary catheter
- Exclusion Criteria:
- • Evidence of volume depletion
- • Baseline Chronic Kidney Disease (CKD) Stage IV or V (estimated GFR \<60 mL/min/1.73m2)
- • History of kidney transplantation
- • Active DNR order or clinical team is not committed to escalating medical care
- • Known history of allergic reaction to furosemide (only for FST)
About Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center in Cincinnati is a leading pediatric healthcare institution dedicated to advancing child health through innovative clinical research and comprehensive patient care. Renowned for its commitment to excellence, the center conducts a wide range of clinical trials aimed at developing and evaluating new treatments and therapies for pediatric populations. With a focus on multidisciplinary collaboration and ethical research practices, Children's Hospital Medical Center strives to improve health outcomes for children while contributing to the broader scientific understanding of pediatric medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Patients applied
Trial Officials
Stuart Goldstein, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials